4//SEC Filing
HANNAH ALISON L. 4
Accession 0001567619-22-014297
CIK 0001501989other
Filed
Jul 20, 8:00 PM ET
Accepted
Jul 21, 4:09 PM ET
Size
6.7 KB
Accession
0001567619-22-014297
Insider Transaction Report
Form 4
HANNAH ALISON L.
Chief Medical Officer
Transactions
- Sale
Common Stock
2022-07-20$1.42/sh−5,602$7,965→ 31,898 total - Award
Common Stock
2022-07-19+15,000→ 37,500 total
Footnotes (3)
- [F1]Represents Performance Stock Units ("PSUs") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The first milestone vesting condition was determined to be satisfied upon which 50% of the PSUs vested.
- [F2]Includes 22,500 restricted stock units.
- [F3]The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to a PSU of the Issuer.
Documents
Issuer
CytomX Therapeutics, Inc.
CIK 0001501989
Entity typeother
Related Parties
1- filerCIK 0001645600
Filing Metadata
- Form type
- 4
- Filed
- Jul 20, 8:00 PM ET
- Accepted
- Jul 21, 4:09 PM ET
- Size
- 6.7 KB